Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > LABS is only one with GMP in Canada & USA !!!!
View:
Post by 1hot-techwoman on Oct 17, 2024 9:02am

LABS is only one with GMP in Canada & USA !!!!

Labs will be bought out in the near future because of this. $$$ IMHO 


MediPharm Labs to become the first commercial cannabis company in Canada to receive Good Manufacturing Practice ("GMP") site registration from the United States Food and Drug Administration ("US FDA").

MediPharm Labs remains committed to its mission of providing high-quality, innovative cannabis solutions globally and ensuring the highest standards of production and compliance. The company will continue to focus on growing internationally, while maintaining its strong debt free balance sheet and enhancing profitability.

Comment by alleyesonme on Oct 17, 2024 9:43am
Definitely getting the vibe something along the lines of merger or buyout...Keith makes 360k a year...good terms departure for him to join the B O D...typically the CEO takes on the president role...very interesting development here...
Comment by Solid1 on Oct 17, 2024 10:15am
I can't imagine the board or the CEO letting this baby out of their hands. DEA just recently agreed to the FDA's new 2-step plan... why would they give up their shares for a few cents? 
Comment by Starkicker on Oct 17, 2024 10:18am
I always read too much into the comings and goings of management. Usually it's just a personal decision and they're looking for another challenge, not anything to do with the state of the company. Impossible to speculate.
Comment by QContinuum1 on Oct 17, 2024 11:11am
This represents nothing more than a sacrificial lamb event and it clearly shows that: 1) Damn near nothing of substance should be expected as far a growth goes in the near term and 2) Pidduck and the BOD realize that the last while has been a wasted opportunity and Stachan just hasn't done the job. Punting Stachan to the BOD is likely a mitigation measure to not pay out some kind of retention ...more  
Comment by subaru1 on Oct 17, 2024 11:34am
Well said QC, positiv side is the cost saving, New shipment, new contract, new product, growth this is what we need. Curiously i am receiving Email from Medipharm with major price reduction on their CBD product ???? the demand is not there or what.
Comment by 1hot-techwoman on Oct 18, 2024 10:42am
Somthing is starting to happen behind the scenes as volume is picking up !!! New CEO? Merger? Acquisition? :) $$$$
Comment by srtman03 on Oct 18, 2024 11:11am
Time to BUY !!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities